Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers

January 02, 2025 04:17 AM EST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers
Image source: Kalkine Media

SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will present its latest breakthrough immunocytokine, FP008, on Jan 14, 2025, at the Biotech Showcase investor conference, following J.P. Morgan Healthcare Week. This bifunctional anti-PD-1/IL-10M fusion protein is designed to address populations refractory to anti-PD-1 therapies. The presentation will introduce Fapon Biopharma's continued strength and innovation in the development of anticancer drugs.

FP008 is a proprietary and patented drug candidate using Fapon Biopharma's cutting-edge antibody technology. As a first-in-class biologic, FP008 uniquely combines an engineered IL-10 monomer (IL-10M) with an anti-PD-1 antibody, significantly reducing the challenging toxicity associated with wild-type IL-10, while activating IL-10M at the target site. This represents a critical advancement in the field of immuno-oncology. FP008 not only inhibits exhausted CD8+ T cells apoptosis and enhances their functional activity in vitro, but also significantly increases the proportion of CD8+ T cells in tumor microenvironment, exhibiting a potent anti-tumor effect in vivo. Additionally, FP008 has demonstrated excellent druggability and good tolerability in cynomolgus monkeys toxicity studies at doses up to 10 mg/kg, confirming its viability as a candidate drug.

 "FP008 represents a significant leap forward in our quest to develop more effective and safer immunotherapies for cancer patients," says Max Wang, Business Development Director at Fapon Biopharma. "By addressing the critical unmet need of PD-1 therapy-resistant tumors, FP008 has the potential to transform treatment paradigms and improve outcomes for patients who have limited options."

Fapon Biopharma plans to submit an Investigational New Drug (IND) application for FP008 to the U.S. Food and Drug Administration (FDA) in early 2025. The company remains committed to developing more effective and accessible therapeutics through consistent innovation and collaboration. Fapon Biopharma aims to present FP008 to a global audience and seek strategic partners to drive its development, ultimately benefiting cancer patients worldwide.

Biotech Showcase Presentation Information

Title: Overview of Fapon Biopharma and IL-10 Antibody Fusion Programs

Summary: This presentation highlights Fapon Biopharma's integrated platforms for innovative biologics development, with a focus on FP008, a novel bifunctional anti-PD-1/IL-10M fusion protein designed to address anti-PD1 refractory/resistance populations. Fapon Biopharma seeks global partners for licensing and co-development opportunities.

Speaker: Max Wang

Date: Tuesday, January 14 2025

Time: 3:45PM

Track: Franciscan B (Ballroom Level)

About Fapon Biopharma

Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases, and other conditions with unmet medical needs. Leveraging advanced technologies, Fapon has built sophisticated drug discovery platforms, including an antibody discovery platform based on leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a differentiated pipeline of leading drug candidates, Fapon has established capabilities across the entire drug development process, from discovery and preclinical research to Chemistry, Manufacturing and Controls (CMC) and early clinical development. Committed to innovation, Fapon strives to deliver safer, more efficacious, affordable, and accessible biologics for everyone.

Website: https://en.faponbiopharma.com


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media Incorporated (“Kalkine Media, we or us”), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used in the Content are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Canadian AI All-Stars: Unveiling the Top Stocks for 2024

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.